Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Daniel Ross

Foot and Ankle Surgery Flowood, MS Medical Doctor

NPI 1841724408 CMS profile 5701055

104 Burney Dr, Flowood, MS 39232

Open in the dashboard

General payments

$16,353

76 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Ross of Flowood, MS is reported in the CMS Open Payments database as having received $16,353 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,270 20
2024 General $663 13
2023 General $2,360 26
2022 General $10,992 16
2021 General $68 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Ross
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Daniel Ross were reported at $2,270. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Daniel Ross Foot and Ankle Surgery median Middle half National median
2019 $0 $1,327 $279–$5,421 $163
2020 $0 $795 $121–$3,473 $114
2021 $68 $1,289 $201–$4,963 $132
2022 $10,992 $1,539 $270–$6,067 $149
2023 $2,360 $1,117 $257–$5,264 $160
2024 $663 $1,064 $235–$4,944 $164
2025 $2,270 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Arthrex, Inc. $12,451 24 payments
  2. Alon Medical Technology $1,380 6 payments
  3. Stryker Corporation $1,035 13 payments
  4. Zimmer Biomet Holdings, Inc. $407 9 payments
  5. Paragon 28, Inc. $346 3 payments
  6. OSSIO Inc. $144 1 payment
  7. DePuy Synthes Sales Inc. $86 1 payment
  8. Vertex Pharmaceuticals Incorporated $69 4 payments
  9. Organogenesis Inc. $68 2 payments
  10. Peerless Surgical Inc. $68 1 payment
  11. Other $299 12 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Grant $10,000 1 payment
  2. Travel and Lodging $3,540 14 payments
  3. Food and Beverage $2,813 61 payments
Products named General payments · program years 2021–2025
  1. INFINITY ADAPTIS $477 5 payments
  2. Product Portfolio $346 3 payments
  3. Trabecular Metal $304 8 payments
  4. AUGMENT INJECTABLE $169 1 payment
  5. PROSTEP $121 2 payments
  6. INBONE $107 1 payment
  7. INFINITY $107 1 payment
  8. ROSA $103 1 payment
  9. TFN-Advance $86 1 payment
  10. NA $86 1 payment
  11. Other $885 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

335

Median for Orthopedic Surgery: 203

Drug cost

$2,082

Median for Orthopedic Surgery: $1,433

Branded share of claims

8.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 34 $927
Meloxicam Generic 167 $464
Ondansetron Odt Ondansetron Brand 15 $191
Gabapentin Generic 43 $149
Ibuprofen Generic 11 $88
Oxycodone Hcl Generic 16 $74
Methylprednisolone Generic 15 $69
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 14 $61
Tramadol Hcl Generic 20 $59

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 124 billing codes

Paid by Medicare

$128,384

Of which drugs: $24,809

Medicare patients

390

Average age 73

Services billed

3,662

265 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 35%
Ischemic heart disease 26%
Depression 25%
Chronic kidney disease 20%
Osteoporosis 20%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 32 1,840 $190

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record